BCL2 and acute myeloid leukemia: Similar to the synergism observed between obatoclax, a Mcl-1/Bcl-2 inhibitor, and TRAIL [30], another Mcl-1/Bcl-2 antagonist, venetoclax, showed synergism with the TRAIL fusion protein, eftozanermin alfa, in acute myeloid leukemia cells, as well as in patients [53].